Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




Revenue increases by 6.6% in financial year 2008/2009 - EBIT margin
climbs to 11.9% - Operative cash flow up by 60%

(Jena, 14 December 2009) The medical technology provider Carl Zeiss
Meditec closed its financial year (end: 30 September 2009) on a high.
In spite of difficult general conditions, the Company increased its
revenue and earnings. The Company's excellence programme RACE 2010,
which was implemented in summer 2008, was an important driver of this
positive trend.

Carl Zeiss Meditec generated consolidated revenue of EUR 640.1
million in financial year 2008/2009, compared with EUR 600.1 million
the previous year. Earnings before interest and tax (EBIT) increased
by 11.5% in the reporting period to EUR 76.1 million (previous year:
EUR 68.2 million). The EBIT margin increased accordingly, from 11.4%
in the previous year to 11.9% in financial year 2008/2009. Cash flow
from operating activities rose by as much as 60% to EUR 87.4 million.
The results achieved in financial year 2008/2009 thus validate the
Company's policy of focusing on sustainable growth. The Supervisory
Board and Management Board shall therefore propose to the Annual
General Meeting 2010 a dividend of EUR 0.18.

"I would like to thank in particular our dedicated and competent
employees around the world, without whose ideas and extraordinary
commitment this successful financial year would not have been
possible. Many of our customers are impressed to see the passion with
which our employees work day after day to find solutions for the
hospital and medical practice environment," says Dr. Michael Kaschke,
President and CEO of Carl Zeiss Meditec AG.

Regionally, the Company achieved its highest growth rates in the
"Asia/Pacific" region in financial year 2008/2009, where growth was
21.1%. The "Americas" region continues to account for the largest
share of revenue, generating 35.6%.

The strategic business units Ophthalmic Systems and Microsurgery
increased their revenue in financial year 2008/2009 by 9.0% and 3.8%,
respectively. The strength of the US dollar and the Japanese yen
against the euro had a positive effect on both these business units
in the first half of the year. Revenue in the Surgical Ophthalmology
SBU grew by 6.8%.

Dr. Michael Kaschke explains: "This growth also highlights that we
used the last year successfully to fully integrate our acquired
units. This was an important step, as it is only after integration
that the full value of acquisitions can be realised. Carl Zeiss
Meditec is now ready for new opportunities and is actively searching
for them."

The Company's equity ratio was 71.6% as of 30 September 2009 (30
September 2008: 70.0%). Net cash amounted to EUR 252.0 million at the
end of the financial year (30 September 2008: EUR 210.4 million).

"Our professed aim is to achieve sustainable, profitable growth. We
are continuously working towards this goal with our RACE 2010
programme. We expect revenue growth in financial year 2009/2010 to
again be at least on a par with market growth. We aim to at least
maintain our already very good operating profitability (EBIT margin),
without foregoing necessary investments, in order to ensure
continuous growth in value-added for the Company," emphasised Dr.
Kaschke.

Revenue by strategic business unit
Figures in EUR '000: Financial year 2007/2008 / Financial year
2008/2009 / Change from previous year
Ophthalmic Systems / 285,010 / 310,788 / 9.0%
Surgical Ophthalmology / 73,990 / 79,036 / 6.8%
Microsurgery / 241,190 / 250,265 / 3.8%

Revenue by region
Figures in EUR '000: Financial year 2007/2008 / Financial year
2008/2009 / Change from previous year
Germany / 54,797 / 56,413 / 2.9%
EMEA / 194,105 / 188,320 / -3.0%
Americas / 212,767 / 227,674 / 7.0%
Asia / Pacific / 138,522 / 167,682 / 21.1%


 
--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

WKN: 
531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share, 
TecDAX;
Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse 
Stuttgart, 
Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, 
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr 
in Niedersächsische Börse zu Hannover, 
Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in 
Frankfurter Wertpapierbörse;



Copyright © Hugin AS 2009. All rights reserved.